Publications

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Key

International journal of cancer

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

15-05-2024

Cancer

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

01-05-2024

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-04-2024

European journal of cancer (Oxford, England : 1990)

The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.

01-03-2024

EClinicalMedicine

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

01-03-2024

Journal for immunotherapy of cancer

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

31-01-2024

Cancer immunology, immunotherapy : CII

Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.

27-01-2024

European journal of cancer (Oxford, England : 1990)

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

01-01-2024

Pigment cell & melanoma research

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

01-01-2024

Nature medicine

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.

01-12-2023

Cancers

Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.

15-11-2023

Cancer immunology, immunotherapy : CII

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

01-11-2023

Cancer discovery

Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

01-11-2023

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

01-09-2023

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-08-2023

International journal of cancer

Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.

15-07-2023

Journal for immunotherapy of cancer

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

01-07-2023

The Lancet. Oncology

Adjuvant immune checkpoint blockade revisited.

01-07-2023

International journal of cancer

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.

15-06-2023

European journal of cancer (Oxford, England : 1990)

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

01-06-2023

European journal of immunology

Acidity-mediated induction of FoxP3⁺ regulatory T cells.

01-06-2023

Cancer chemotherapy and pharmacology

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

01-06-2023

Nature medicine

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

01-06-2023

Journal of immunotherapy (Hagerstown, Md. : 1997)

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.

01-06-2023

Nature reviews. Clinical oncology

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.

01-06-2023

Cancers

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

26-05-2023

The Journal of experimental medicine

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

01-05-2023

European journal of cancer (Oxford, England : 1990)

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

01-05-2023

Journal of translational medicine

The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.

18-04-2023

Cancer immunology research

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

03-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

01-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Cancer research communications

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.

01-04-2023

Immuno-oncology technology

Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.

01-03-2023

European journal of cancer (Oxford, England : 1990)

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.

01-03-2023

European journal of cancer (Oxford, England : 1990)

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.

01-03-2023

British journal of cancer

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.

01-03-2023

Cardiovascular and interventional radiology

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.

01-03-2023

Cancers

Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).

28-02-2023

Nature communications

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-02-2023

Melanoma research

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

01-02-2023

Cancers

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

07-01-2023

Annals of surgical oncology

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

01-01-2023

BMC cancer

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

30-12-2022

The New England journal of medicine

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

08-12-2022

Melanoma research

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

01-12-2022

Data in brief

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.

01-12-2022

JAMA oncology

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

01-12-2022